MetLife Investment Management LLC Has $49.43 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• MetLife Investment Management LLC reduced its stake in Thermo Fisher Scientific Inc. by 1.9%, selling 1,894 shares, and now holds 99,340 shares valued at approximately $49.4 million.
• Thermo Fisher Scientific reported earnings of $5.36 per share for the last quarter, surpassing analyst expectations, with total revenue reaching $10.86 billion.
• The company declared a quarterly dividend of $0.43 per share, with a dividend yield of 0.3%, set to be paid on October 15th.

MetLife Investment Management LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 99,340 shares of the medical research company's stock after selling 1,894 shares during the period. MetLife Investment Management LLC's holdings in Thermo Fisher Scientific were worth $49,432,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Thermo Fisher Scientific by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after purchasing an additional 230,382 shares during the last quarter. Northern Trust Corp increased its position in shares of Thermo Fisher Scientific by 13.2% during the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock worth $2,034,107,000 after purchasing an additional 455,004 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Thermo Fisher Scientific by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after purchasing an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA increased its position in shares of Thermo Fisher Scientific by 7.2% during the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after purchasing an additional 193,378 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Thermo Fisher Scientific by 11.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,420,949 shares of the medical research company's stock worth $1,259,450,000 after purchasing an additional 257,462 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 28,896 shares of company stock valued at $13,603,438. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded up $3.86 during mid-day trading on Friday, reaching $493.60. 498,831 shares of the company's stock were exchanged, compared to its average volume of 2,442,697. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock has a market capitalization of $186.39 billion, a PE ratio of 28.54, a price-to-earnings-growth ratio of 2.61 and a beta of 0.74. The business's fifty day simple moving average is $450.59 and its 200-day simple moving average is $455.26. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the company earned $5.37 earnings per share. The company's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TMO. William Blair began coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating for the company. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Finally, Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.